CV: ARRHYTHMIAS, BRADYCARDIA, HF, orthostatic hypotension, peripheral vasoconstriction, PULMONARY EDEMA.
Derm: ERYTHEMA MULTIFORME, EXFOLIATIVE DERMATITIS, itching, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.
EENT: blurred vision, dry eyes, nasal stuffiness.
Endo: hyperglycemia, hypoglycemia (↑ in children).
GI: constipation, diarrhea, nausea.
GU: erectile dysfunction, ↓ libido.
MS: arthralgia, back pain, muscle cramps, myopathy.
Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares, paresthesia.
Resp: bronchospasm, wheezing.
Misc: drug-induced lupus syndrome, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).
Hemangeol, Inderal, Inderal LA, Inderal XL, InnoPran XL
Therapeutic Classification: antianginals, antiarrhythmics (Class II), antihypertensives, vascular headache suppressants
Pharmacologic Classification: beta blockers
Absorption: Well absorbed but undergoes extensive first-pass hepatic metabolism.
Distribution: Moderate CNS penetration. Crosses the placenta; enters breast milk.
Protein Binding: 93%.
Metabolism/Excretion: Almost completely metabolized by the liver (primarily for CYP2D6 isoenzyme) (the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly ↑ propranolol concentrations and an ↑ risk of adverse effects).
Half-life: 3.4–6 hr.
(cardiovascular effects)
†Following single dose, full effect not seen until several wk of therapy.
